

27th March 2016 - Powai, Mumbai.

"Dia League was held at Hotel Renaissance, Near Chinmayanand Ashram, Powai, Mumbai, Maharashtra - 400087.. It was planned and organized by of Asian Society of Continuing Medical Education.

The sole objective of the CME was to update the practicing doctors about Diabetes mellitus, level of morbidity and mortality due to diabetes and its associated spectrum of complications and diabetes management as the disease is now highly visible across all societies within India.

The session was open with an introductory session by Asian Society of continuing Medical Education and followed by the scientific agenda.

Date : 27th March 2016.

Venue : Hotel Renaissance, Near
Chinmayanand Ashram, Powai, Mumbai,
Maharashtra- 400087.

Total Participants : **65**

TOPICS

- 1. The role of combination therapies in early, Intensive management of newly Diagnosed**
- 2. DPP-4 Inhibitors: have we optimized their role in the treatment of patients with Type 2 Diabetes**
- 3. A futuristic vision in diabetes management**
- 4. Placement of Sulphonylurea in the present scenario?**
- 5. The act of balancing between the newer treatment options in T2DM**
- 6. Yes to DPPIV Inhibitors**
- 7. Yes to SGLT2 Inhibitors**
- 8. Cross Talk : Managing Diabetic patient with CV comorbid conditions
Cardiologist Perspective and Diabetologist Perspective**

Dia-League

MODERATOR, CHAIRPERSONS AND FACULTIES



Dr. Manoj Chadha
MD, DM (Endocrinology)

Consultant Endocrinologist



Dr. Mahesh Padsalge
MBBS, MD (Medicine), D.F.I.D ,
PGDCR

Consulting Diabetologist



Dr. Sharat Kolke
MBBS, MD, DNB

**Consultant Consultant in
Internal Medicine**



Dr. Suresh Sawardekar
MBBS, MD, PGDHSC, MHSC

Consultant Diabetologist



Dr. Mangesh Tiwaskar
MD (Med), FACP, FICP, FSGI

**Consultant Physician &
Diabetologist**




Dr. Rommel Idnani
MBBS, MD(Medicine)

Consultant Physician



Dr. Sanjay Agarwal
MBBS,MD (Medicine)

**Director, Aegle Clinic-
Diabetes Care.
Consultant Physician and
Diabetologist**



Dr. Seetha Raju
MBBS, MD (Medicine)

Consultant Physician



Dr. Ameya S. Joshi
M.B.B.S., M.D., DM (Endocrinology)

Consultant Endocrinologist



Dr. Vijay Chile
MBBS, MD (Medicine)

**Consultant Physician &
Diabetologist**

Dia-League

MODERATOR, CHAIRPERSONS AND FACULTIES




Dr. Sharvil Gadve
MBBS, MD (Medicine), DM
(Endocrinology)

Consultant Endocrinologist



Dr. Mahesh K Shah
M.B.B.S., M.D.(Medicine), DM
(Cardiology)

**Consultant Diabetes &
Endocrinology
Consultant Invasive**



Dr. Sadanand R Shetty
DM (Cardio), MD(Med)

Consultant Cardiology



Dr. Altamash Shaikh
M.B.B.S. DNB (Gen. Med), MNAMS
(Endocrinology)

**Consultant Endocrinologist,
Diabetologist And Metabolic
Physician**

1. **Dr. Mangesh Tiwaskar** Talked on The role of combination therapies in early, Intensive management of newly diagnosed Type 2 Diabetes with marked glycaemia.

- Highlighted Decision point: Which of the options would you choose for this patient?
- Highlighted Diabetes Remission after Intensive Insulin Therapy in New Onset T2DM.
- Highlighted Insulin and its Barriers...
- Early combination therapy for the treatment of type 2 DM: Systematic Review and Meta analysis.
- Highlighted Initial Management of severe Hyperglycemia in patients with Type 2 Diabetes: An Observational Study.
- The ideal components for combination therapy?
- Highlighted Need for an early and combination approach to type 2 diabetes management

2. **Dr. Sanjay Agarwal and** .Talked on- DPP-4 Inhibitors: Have we optimized their role in the treatment of patients with Type 2 Diabetes

- Highlighted Decreased Insulin, Elevated Glucagon, and Hyperglycemia in Type 2 Diabetes.
- Highlighted Reduced Incretin Effect in Type 2 Diabetic Patients
- Highlighted Type 2 Diabetes is a Global Cardio-metabolic Risk (CMR)

- Highlighted DPP4 inhibitors (gliptins) is hypoglycemic class that inhibiting the action of DPP4 (which degrade the action of GLP-1 to convert it to inactive form)
- Highlighted DPP4 inhibitors drugs.
- Highlighted Efficacy as Monotherapy compared to Metformin comparable efficacy at 2 yrs.

3. **Dr. S. Sawardekar** Talked on- A futuristic vision of diabetes mngnt. Case study of recurrent hypoglycaemia.

- Role of Incretin in Glucose Homeostasis.
- DPP-4 Inhibitor: Monotherapy
- DPP-4 Inhibitor: Combination Therapy
- Clinical Properties of DPP-4 Inhibitors.
- safety of SGLT2 inhibition.
- Clinical Interventions in Type 1 Diabetes

4. **Dr. Seetha Raju and** Talked on - Placement of Sulphonylurea in the present scenario?

- Highlighted History.
- Highlighted Insulin Secretion (Glimepiride).
- Showed Therapeutic actions
- Highlighted Attributes of sulfonylureas
- Highlighted IDF Global Guideline for Type 2 Diabetes.
- Glimepiride + Metformin Combination vs Monotherapy
- Highlighted ADA and EASD algorithm for the management of type 2 diabetes.
- Type 2 Diabetes is a Dual Problem

5. **Dr. Ameya Joshi and Dr. Sharvil Gadve** Talked on – The act of balancing between the newer treatments options in T2DM.

I. Yes to DPP 4 inhibitors.

- The Incretin Effect in Subjects Without and With Type 2 Diabetes
- DPP4 inhibitors drugs.
- Comparative Effectiveness of Treatment Options: Intermediate Outcomes.
- The Glucose dependent action of DPP4i Vs SUs.
- DPP4-i addresses the unmet need in the management of diabetes.
- Cardiovascular and heart failure safety profile of vildagliptin.
- Effect of dipeptidyl peptidase-4 inhibitor, vildagliptin on plasminogen activator inhibitor-1 in patients with diabetes mellitus.

II. Highlighted Yes to SGLT2.

- Unmet Needs With Conventional Antihyperglycemic Therapies
- The Kidneys Play an Important Role in Glucose Control.
- Rationale for SGLT2 Inhibitors.
- Effects of SGLT2 Inhibitors
- SGLT2 Inhibitors in Phase 3 Development.
- Empagliflozin: Change in Plasma Glucose in the Fasting State.
- Changes from Baseline in Fasting Plasma Glucose in Phase 3 Dapagliflozin Studies.
- Glycosuria : Weight loss and BP reduction
- Reduction In Leptin/Adiponectin Ratio.

6. Dr. Mahesh Shah & Dr. Altamash Shaikh Talked on – Cross Talk : Managing Diabetic patient with CV co morbid conditions.

I Highlighted Cardiologist perspective

- Metabolic Syndrome: CHD Prevalence, Risk of Death, Risk of Developing DM, Risk of CVD Events, Risk of Myocardial Infarction.
- Recommendation:-
- Hypertension/Blood Pressure control
- Dislipidemia/Lipid Management
- Glycemic, Blood pressure, Lipid control in adults.
- Antiplatelet Agents.
- Smoking Cessation, Coronary Heart Disease treatment.

II Highlighted Diabetologist perspective.

- Chronic hyperglycemia vs. Frequent acute glycemic variability
- Oxidative stress secondary to hyperglycemia leads to vascular complications.
- Drugs used in the management –Biguanides, Sulfonylureas, Glitazones ,
- Alpha Glucosidase inhibitors.
- Combined Antihyperglycemic treatment.

Dia-League

SNAPSHOTS



Dia-League

SNAPSHOTS

